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Abstract
20 % of ischemic stroke appear to originate from carotid artery atherosclerotic disease. Serum biomarkers reflecting the ac-
tivity of atherosclerotic process and may help for estimate risk of acute cerebrovascular events. Several serum inflammatory markers 
have been proposed for risk assessment, but their prognostic role less known.
The aim of this study is to clarify the prognostic value of biomarkers of atherosclerosis lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) and E-selectin in patients with symptomatic and asymptomatic carotid stenosis. 
Materials and methods. The study involved 106 patients with atherosclerotic carotid stenosis > 50 % (74 men and 32 wo-
men, mean age 62.6 ± 0.9) from which 76 symptomatic (35 with acute ipsilateral atherothrombotic stroke and 41 after carotid end-
arterectomy) and 30 asymptomatic patients. The control group consisted of age- and sex-matched 20 healthy subjects. The level of 
serum Lp-PLA2 and E-selectin was determined using a commercially available enzyme-linked immunosorbent assay kit.
Results. The level of Lp-PLA 2 was in general significantly higher (p < 0.05) in patients groups than in the control group 
and most high Lp-PLA2 concentration was in groups of symptomatic patients who underwent carotid endarterectomy. The level of 
E-selectin in the study patients was significantly higher than in the control group (p < 0.05). The correlation of Lp-PLA 2 with 
E-selectin was significant for total patients (R = 0.365664, p = 0.00085) and group after carotid endarterectomy (R = 0.429143, 
p = 0.01796), but not for asymptomatic group (p > 0.05). Receiver Operating Characteristics curves of logistic regression models 
which takes into joint both indicators was specificity and sensitive for predicting the occurrence of ischemic stroke.
Conclusion. Conducted study show that the levels of Lp-PLA 2 and E-selectin have a significant impact on the development 
of stroke in patients with atherosclerotic carotid stenosis and can be used to predict it. A multidimensional model of the dependence 
of the probability of stroke on a linear combination of Lp-PLA 2 and E-selectin allows to obtaining significantly higher characteris-
tics of the accuracy of stroke prediction than models with each factor alone.




Carotid artery atherosclerotic stenosis is a common cause of ischemic stroke [1]. Around 
20 % of it appear to originate from carotid plaques. It is well recognized that the presence of 
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atherosclerotic disease in the carotid arteries increases a substantial risk of ipsilateral cerebrovas-
cular events, with reported annual ischemic stroke rates ranging from 0.35 % to 1.3 % in asymp-
tomatic patients with moderate stenosis to approximately 5 % for severe asymptomatic carotid 
artery stenosis [2]. Clinical, biochemical, and ultrasound markers, magnetic resonance (MRI) 
plaque characteristics or transcranial cerebral Doppler signals have been proposed as indicators 
of a high-risk plaque. It is well accepted that circulating biomarkers, including C-reactive protein 
and interleukin-6, reliably predict major cardiovascular events, including myocardial infarction or 
death. However, the relevance of biomarkers of systemic inflammation to atherosclerosis progres-
sion in the carotid artery is less established. Other inflammatory biomarkers, lipids, interleukins, 
homocysteine, and adipokines may be useful in quantifying carotid disease-related risk. Some se-
rum biomarkers combined with image features may assist vascular specialists in selecting patients 
at high risk for stroke [3–5].
The aim of this study to clarify the prognostic value of biomarkers of atherosclerosis lipo-
protein-associated phospholipase A2 (Lp-PLA2) and E-selectin in patients with symptomatic and 
asymptomatic carotid stenosis. 
2. Materials and methods
The study included patients, who were hospitalized in the period from November̀ 2018 to 
January 2020 at the City Clinical Hospital No. 7 of the Kharkiv City Council, Ukraine.
The 106 patients with atherosclerotic carotid stenosis (74 men and 32 women, aged from 31 
to 74 years, mean 62.6 ± 0.9) were involved in the study. The criterion for involving were athe-
rosclerotic carotid stenosis > 50 %, absence history of atrial fibrillation, intracranial haemor-
rhage, inflammatory diseases, cancer. The symptomatic groups included 35 patients (group 1) 
had presented with acute non-lacunar ischaemic stroke in ipsilateral internal carotid artery (ICA), 
NIHSS 3–9 and 41 patients (group 2) who suffered from ischaemic stroke and underwent carotid 
endarterectomy (CEA) on ipsilateral side with the mean follow-up period 35 months. When deter-
mining the indications for surgical intervention guided by generally accepted recommendations. 
Asymptomatic group (group 3) included 30 patients who had acute ischemic event in clinical history. 
Neuroimaging (CT or MRI) was performed in all patients. The control group consisted of 
31–56 age- and sex-matched 20 healthy subjects who visited our hospital for a routine physical 
check-up and without a history of cardiac disease, hypertension or diabetes and having normal 
findings on physical examination, Doppler ultrasound and echocardiography. 
Informed consent was obtained from all participants and the study was approved 
by the Bioethics Committee of Kharkiv Medical Academy of Postgraduate Education (report No. 9 
of 21th November 2018) in accordance with the Code of Ethic of the World Medical Associa-
tion (Helsinki Declaration). 
In all patients’ traditional risk factors as arterial hypertension, smoking, overweight, diabe-
tes mellitus, myocardial infarction history and hypercholesterinemia was assessed.
All patients underwent duplex sonography. Carotid atherosclerotic examinations were per-
formed with a high-resolution (10.0 MHz) color Doppler ultrasound by scanner «MINDRAY DC-40». 
The degree of ICA stenosis was determined by the European Carotid Surgery Trial (ECST) method [6].
The level of serum Lp-PLA2 was determined using a commercially available enzyme-linked 
immunosorbent assay kit (ELISA) Elabscience, USA. E-selectin was measured using commercially 
available (ELISA) kit (Elabscience, USA).
Descriptive statistics of data are presented as M ± m or Me [LQ; UQ] for continuous va-
riables (where M – mean value, m – standard error of mean, Me – median, LQ and UQ – lower 
and upper quartiles). Counts and proportions (%) are reported for qualitative variables. To test 
significance of differences of normally distributed quantitative variables between several groups 
of patients Fisher’s ANOVA was applied (the obtained value of test statistic is denoted by F further 
in the paper). In cases when within-group distributions deviate from normality non-parametric 
Kruskal-Wallis ANOVA was used (the obtained values of test statistic is denoted by KW H) for 
the same purpose. To compare numerical values in two groups of patients Mann-Whitney U-test 
was applied (the values of test statistic is denoted by MW U in the paper). To test significance of 
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differences between groups for categorical variables Pearson’s c2 test for r´c contingency tables was 
applied (the va lues of test statistic is denoted by c2 in the paper). The correlations between variables 
were assessed by Spearman correlation coefficient. The significance of Lp-PLA 2 and E-selectin in 
determining the presence of stroke was assessed by the analysis of ROC-curves (Receiver Operating 
Characte ristics) of logistic regression models. The statistical analysis and inference was performed 
at 95 % confidence probability, so p-values less than 0.05 were considered statistically significant. 
STATISTICA 13 software package (TIBCO Software Inc., USA) was used for data analysis.
3. Results
Baseline and clinical characteristics of patients with carotid stenosis are shown in Table 1. 
All patients had ≥1 atherosclerotic risk factors. It showed a trend toward a higher prevalence of cur-
rent smoking, high total cholesterol level and diabetes mellitus in symptomatic patients groups – 
with acute stroke and history of stroke and CEA.
Table 1








Age, year 62.6 ± 0.9 61.6 ± 1.5 59.7 ± 1.3 67.7 ± 1.8*
Gender, male/female 74 (69.8 %)/32 (30.2 %) 29 (82.9 %)/6 (17.1 %) 33 (80.5 %)/8 (19.5 %) 12 (40.0 %)/18 (60.0 %)*
Arterial Hypertension 89/84.0 % 31/89.0 % 30/73.2 % 28/93.3 %
Current smokers 64/60.4 % 30/85.7 % 22/53.6 % 12/40.0 %*
Total cholesterol 
≥5 mmol/l
63/67.7 % 23/65.7 % 34/82.9 % 17/56.6 %
Low density cholesterol 
≥2 mmol/l
87/93.5 % 33/94.3 % 35/85.4 % 30/100.0 %
Body mass index ≥25 70/66.0 % 25/71.4 % 25/61.0 % 20/66.7 %
Diabetes mellitus 7/6.6 % 4/11.4 % 2/4.9 % 1/3.3 %
Myocardial infarction 
history
10/9.4 % 3/8.6 % 3/7.3 % 4/13.3 %
Degree of ipsilateral carotid artery stenosis
50–69 % 49/46.2 % 20/57.1 % 6/14.6 % 23/76.7 %*
70–99 % 41/38.7 % 8/22.9 % 26/63.4 % 7/23.3 %*
occlusion 15/14.2 % 7/20.0 % 8/29.5 % 0/0.0 %
Note: * – p < 0.05 comparison between patients with symptomatic and asymptomatic carotid stenosis
The level of Lp-PLA 2 in patients was on average 46.02 [29.51; 79.71] ng/ml, which was 
significantly higher (MW U = 10, p = 1.023136´10–11 < 0.05) than in the control group, in which 
Lp-PLA 2 was observed at the level of 9.92 [4.58; 12.48] ng/ml. Lp-PLA2 concentration was sig-
nificantly higher in groups of symptomatic patients who underwent CEA. Lp-PLA 2 did not differ 
in men and women (MW U = 495.0, p = 0.06387 > 0.05) (Table 2).
The level of E-selectin in the study patients was significantly higher than in the control 
group (MW U = 113.0, p = 3.3011´10–9 < 0.05), however, the differences between the three study 
groups were insignificant (KW H (2.80) = 0.7979, p = 0.6710 > 0.05) (Table 2).
The correlation of Lp-PLA 2 with E-selectin, assessed for total patients, was signifi-
cant (p = 0.00085). In symptomatic group in patients after CEA, the correlation of E-selectin 
with LP-PLA 2 was also statistically significant (p = 0.01796). However in the group of asymptom-
atic stenosis this correlation was absent (p = 0.13977).
Three models of logistic regression to predict the presence of a stroke were developed and 
studied: 1) a one-dimensional model of the dependence of the probability of stroke on the values 
of Lp-PLA 2; 2) one-dimensional model of the dependence of the probability of stroke on the values 
of E-selectin; 3) a multidimensional model of the dependence of the probability of stroke on a linear 
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combination of Lp-PLA 2 and E-selectin. The significance of the studied indicators for predicting 
the development of stroke was assessed by the value of the area under the ROC-curve, as well as the 
overall accuracy, specificity and sensitivity of the obtained model were taken into consideration.
Table 2 
Serum level Lp-PLA 2 and E-selectin in patients with atherosclerotic carotid stenosis with different clinical 
manifestation
Group of patients Lp-PLA2 (ng/ml)M ± m
E-selectin (pg/ml)
M ± m
Control n = 20 9.296 ± 0.935 3.101 ± 0.503
Total n = 106 55.664 ± 3.537* 7.653 ± 0.246*
Group 1 n = 35 46.412 ± 6.421* 8.070 ± 0.430*
Group 2 n = 41 67.645 ± 5.742*, ** 7.497 ± 0.408*
Group 3 n = 30 50.539 ± 5.560* 7.423 ± 0.446*
Note: * – p < 0.05 comparison between patient’s group and control; ** – p < 0.05 comparison between group 1 and group 2
To predict the rate of occurrence of the stroke in fallowness from the level of Lp-PLA 2, 







y( ) . . .Lp_PLA Lp_PLA2 0 987 0 272 2= − ⋅
The statistical significance of the model coefficients assessed by Wald’s criterion allows us 
to conclude that the increase in the level of Lp-PLA 2 has a significant impact on the increase in 
the probability of stroke (p = 0.00039). The overall prediction accuracy is 67 %, but the model has 
a fairly balanced value of specificity and sensitivity, which is expressed by AUC = 0.7535, which 
indicates the average quality of the model (Fig. 1).
Fig. 1. ROC-curve of the logistic regression model for predicting the presence of stroke  
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y E Eselectin selectin( ) . . .= − ⋅2 0595 0 3383
The statistical significance of the coefficients of the model suggests that increasing the level 
of E-selectin has a significant impact on increasing the risk of stroke (p = 0.00029).
Overall prediction accuracy of 70 %, but the prediction of stroke probability based on E-se-
lectin has less balanced values of specificity and sensitivity than a similar model based on the level 
of LP-FLA 2, which is expressed by AUC = 0.7002 (Fig. 2). This value of the area under the ROC 
curve indicates the mediocre quality of the model for predicting the occurrence of stroke on the 
basis of E-selectin.
Fig. 2. ROC-curve of the logistic regression model for predicting the presence of stroke  
based on the level of E-selectin
We have also studied a model of logistic regression, which is approximate to the visibility of 







1 2( , )
;Lp_PLA
y E Eselectin selectin( , ) . . .Lp_PLAP Lp_PL2 2 1392 0 2364 0 0172= − ⋅ − ⋅ A 2.
The model, which takes into joint both indicators, also confirms the statistical significance 
of the influence of the studied factors on the probability of stroke. Having a slightly higher Na-
gelkerke coefficient R2 = 0.2604 than one-dimensional models, this model is characterized by 70 % 
of the overall accuracy of stroke detection and AUC = 0.7482, which indicates the average quality 
of the model (Fig. 3).
Thus, studies conducted show that the levels of Lp-PLA 2 and E-selectin have a signif-
icant impact on the development of stroke and can be used to predict it. The combination of 
Lp-PLA 2 and E-selectin allows to obtain significantly higher characteristics of the accuracy 
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Fig. 3. ROC-curve of the logistic regression model for predicting the presence of stroke  
based on a linear combination of levels of E-selectin and Lp-PLA 2
4. Discussion
The biological mechanisms involving plasma Lp-PLA 2 in the pathogenesis of the athero-
sclerosis are not well-characterized, however there are sufficiency evidence that Lp-PLA2 involved 
in the process of destabilizing atherosclerotic plaques by increasing inflammatory activity [7]. 
Furthermore, atherosclerosis is now recognized as manifestations of vascular inflammation and 
atherosclerotic plaque destabilization and rupture and successive clinical complications depend 
on several inflammatory molecules involved in the atherosclerosis pathogenesis [8]. Lp-PLA 2, 
originally named platelet-activating factor acetylhydrolase (PAF-AH), is an enzyme involved 
in lipoprotein metabolism and inflammatory pathways. In human, 80 % of Lp-PLA 2 circulates 
bound to LDL-cholesterol, 10–15 % circulates with HDL-cholesterol, and the remaining 5–10 % 
circulates with VLDL-cholesterol. Lp-PLA 2 enzymatic activity results in generation of lyso-
phosphotidylcholine (lysoPC) and oxidized non-esterified fatty acids, two pro-inflammatory me-
diators [9]. Several studies have shown that Lp-PLA2 may be a biological marker that is associated 
with lipoprotein metabolism, vascular inflammation and destabilization of atherosclerotic plaque, 
leading to the development of cardiovascular diseases [10]. High Lp-PLA levels have been asso-
ciated with a high risk of cardiovascular events in healthy older adults [11]. An increased level of 
circulating Lp-PLA 2 was found in patients with high-grade carotid stenosis and unstable plaques 
who underwent carotid endarterectomy [12]. With the development of atherosclerosis, adhesion of 
monocytes on the surface of the endothelium is activated by adhesion molecules E-selectin and 
ICAM-1 [13]. In previous study was shown that in atherosclerotic plaque in patients after CEA 
to observe endothelian expression of molecules adhesion VCAM and E-selectin that reflect the 
macrophage burden within plaque lesion and inflammatory activity of atherosclerosis [14]. In-
flammatory factors such as adhesion molecules (ICAM-1 and VCAM-1), CD40 ligands, C-reac-
tive protein and myeloperoxidase (MPO) participate in induction of atherosclerotic disease. The 
lysoPC stimulates macrophage proliferation, up-regulates cytokines and CD40 ligands, and in-
creases the expression of vascular adhesion molecules, implying a complex interaction between 
Lp-PLA 2 and other inflammatory mediators [15]. In this study most high level of Lp-PLA 2 
was observed in symptomatic patients who underwent CEA after ipsilateral stroke. Patients of 
this group was younger, prevalent male with severe carotid stenosis. Closer correlations between 
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in these patients. In our study Lp-PLA 2 has been implicated in inflammation and considered 
as an inflammatory marker that increased in relationship with activation adhesion molecules 
E-selectin. Therefore it is concluded that there is a significant synergistic relationship between 
E-selectin endothelial expression and Lp-PLA 2 in patients with severe degree stenosis and high 
risk of acute cerebrovascular events.
CEA is a proven secondary prophylaxis method for severe carotid stenosis [16, 17], but 
res tenosis is often observed after surgery, which increases the risk of stroke [18]. Asymptomatic 
carotid artery stenosis is a well-recognized risk factor for ischemic stroke and its prevalence in-
creases with severity of degree of stenosis [19]. With stroke risk associated also ultrasound plaque 
features, but best treatment for asymptomatic carotid artery stenosis and prophylactic revascula-
rization still controversial [20]. To identify subgroup of patients at higher risk for ipsilateral stroke 
is important aim. Individual’s tendency to develop inflammation-dependent vascular disease might 
be related to a susceptibility profile based on functional interactions among a number of different 
markers. In our study clarified that the levels of Lp-PLA 2 and E-selectin have a significant impact 
on the development of stroke and can be used to predict it.
Study limitation. First, this study had a relative small sample. Second, estimation of stroke 
occurrence needs long duration of follow-up. 
Prospects for further research. These finding warrant further investigators for estimate 
prognostic role atherosclerotic markers for risk of stroke occurrence. Elevation of atheroscle-
rotic markers in patients with high risk of stroke may be a potential therapeutic target for pre- 
vention strategy.
5. Conclusion 
The present study identified elevated total plasma Lp-PLA 2 level in patients with carotid 
artery stenosis comparable with control group (p < 0.05). Lp-PLA 2 concentration was significant-
ly higher in group of symptomatic patients who underwent CEA (p < 0.05).
The level of E-selectin in study patients was significantly higher than in control 
group (p < 0.05), but the differences between groups are absence.
We demonstrated that the Lp-PLA 2 correlated with serum level of E-selectin (p < 0.05). 
The logistic regression model showed that combination of Lp-PLA 2 and E-selectin allows to pre-
dicting the stroke development with 70 % of the accuracy in patients with carotid artery stenosis.
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